Hot or Not, Stock Market Edition: 11/20/2025

Here’s what’s hot and what’s not in the market today — actionable intel delivered using our proven quant ratings system, Zen Ratings:

• Hot: Gilead Sciences (GILD) is buzzing following a recent drug development; Veracyte (VCYT) gets backing from a prominent investor
• Not: Commerce Bancshares (CBSH) battles investor indifference; is Beyond Meat (BYND) beyond repair? 

P.S. 3 promising income stocks … All of them are A-rated in our quant ratings system. All of them offer impressive dividends. Add them to your watchlist before December — get the complimentary list here.

A note from our sponsors...

🔥 HOT: Gilead Sciences (GILD) is on the up! The stock is making positive moves following the company’s recent announcement that it delivered its first shipment of Lenacapavir HIV-1 capsid inhibitor to Eswatini and Zambia. While the move has been modest — the stock is up about 4% in the past week — optimism is high, with 3 fresh Strong Buy ratings from top-rated analysts in the past few weeks. Looking at Zen Ratings, the investment case for GILD is rock solid. With a Zen Rating of A (96th percentile of stocks we track), the company is especially strong in three key areas: Value, where it earns an A grade, and Financials and Momentum, where it earns Bs. All said, Gilead's combination of positive trial data, fortress fundamentals, and analyst support makes this a cornerstone holding for income and growth investors alike.

🥶 NOT: Despite its reputation as a Dividend King, regional bank Commerce Bancshares (CBSH) is caught in a painful squeeze between solid fundamentals and market indifference. CBSH's problem isn't operational failure, it's underperformance relative to the broader market. Not only is this reflected in the price action (the stock has slumped 15% in the past 3 months), but in its quant rating — CBSH carries a Zen Rating of F (3rd percentile) with cringe-worthy Component Grades of D for Value and Growth. The Sentiment rating of C and Momentum rating of C indicate that even income-focused investors are losing patience with the stock's lackluster performance. The bottom line? CBSH isn’t great enough to buy at current valuations when better opportunities exist elsewhere. (See more banking stocks with better ratings here.)

🔥 HOT: Genomics diagnostics specialist Veracyte (VCYT) just got a major vote of confidence from one of Wall Street's most influential investors. Cathie Wood's ARK Invest increased its stake in VCYT during Q3 2025, signaling strong conviction in the company's disruptive innovation potential. The stock has responded accordingly, climbing 5% in the past week. VCYT's fundamentals back up the enthusiasm. The company carries a stellar Zen Rating of A (ranking in the 96th percentile of stocks we track), powered by above-average Sentiment and Safety Component Grades that reflect investor confidence and operational stability. The combination of strong analyst sentiment and ARK's endorsement indicates the stock could see more upside in the near term.

🥶 NOT: The hits just keep on coming for Beyond Meat (BYND) — and not in a good way. Following a brief rally last month, the stock has been on a steady descent to the tune of a 30% drawdown in the past month. The company is leaving bad news detritus all along the way — most recently, securities law firm Bleichmar Fonti & Auld LLP announces an investigation into BYND for potential violations of the federal securities laws. Sadly, the fundamentals look as dismal as the news cycle. The stock has an F (Strong Sell) Zen Rating, with D or F Component Grades in most key areas, including Financials, Momentum, Value, Sentiment, and from our proprietary AI rating. The bottom line? BYND may be beyond repair — avoid at all costs unless you’re considering stocks to short. 

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.